Suppr超能文献

咪唑啉受体:构效关系定性研究以及曲唑啉和苄唑啉的发现。两种具有高亲和力和前所未有的选择性的配体。

Imidazoline receptors: qualitative structure-activity relationships and discovery of tracizoline and benazoline. Two ligands with high affinity and unprecedented selectivity.

作者信息

Pigini M, Bousquet P, Carotti A, Dontenwill M, Giannella M, Moriconi R, Piergentili A, Quaglia W, Tayebati S K, Brasili L

机构信息

Dipartimento di Scienze Chimiche, Università di Camerino, Italy.

出版信息

Bioorg Med Chem. 1997 May;5(5):833-41. doi: 10.1016/s0968-0896(97)00009-6.

Abstract

The observation that all the attempts to characterize imidazoline (I) receptors have been carried out with non-selective or poorly selective ligands prompted us to undertaken research aimed at developing selective ligand(s). In previous work using, as a starting point, cirazoline I, a potent alpha 1-adrenergic receptor agonist that also binds to I receptors, we showed that removal of the cyclopropyl ring (2) retains high affinity for I2 receptors while reducing alpha 1-adrenergic agonist activity. However, it was felt that this residual, albeit modest, alpha 1-adrenergic agonist activity might diminish the usefulness of compound 2, and we now report on our continuing efforts in this field. Starting from compound 2, we first eliminated the alpha 1-agonist component by isosteric replacement and then, by means of conformational restrictions on compound 7, succeeded in discovering tracizoline (9) and benazoline (12). These two new ligands with high affinity (pKi value 8.74 and 9.07, respectively) and unprecedented selectivity with respect to both alpha 2- (I2/alpha 2 7,762 and 18,621) and alpha 1- (I2/alpha 1 2,344 and 2,691) adrenergic receptors, are valuable tools in the study of I receptor structure and function. In addition, the large number of derivatives studied has allowed us to establish congruent qualitative structure-activity relationships and identify some structural elements governing affinity and selectivity.

摘要

所有表征咪唑啉(I)受体的尝试均使用非选择性或选择性较差的配体进行,这一观察结果促使我们开展旨在开发选择性配体的研究。在之前的工作中,我们以强效α1 - 肾上腺素能受体激动剂西拉唑啉I为起点,该激动剂也能与I受体结合。我们发现去除环丙基环(2)后对I2受体仍保持高亲和力,同时降低了α1 - 肾上腺素能激动剂活性。然而,人们认为这种残留的、尽管适度的α1 - 肾上腺素能激动剂活性可能会降低化合物2的实用性,我们现在报告我们在该领域的持续努力。从化合物2开始,我们首先通过等排取代消除了α1 - 激动剂成分,然后通过对化合物7进行构象限制,成功发现了曲唑啉(9)和贝那唑啉(12)。这两种新配体对α2 - (I2/α2分别为7,762和18,621)和α1 - (I2/α1分别为2,344和2,691)肾上腺素能受体具有高亲和力(pKi值分别为8.74和9.07)和前所未有的选择性,是研究I受体结构和功能的有价值工具。此外,所研究的大量衍生物使我们能够建立一致的定性构效关系,并确定一些决定亲和力和选择性的结构元件。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验